All News

The rate of uninsured Americans will rise to 8.9% over the next decade; Senator Bernie Sanders (I, Vermont) wants a government watchdog to investigate why women are still being charged for contraception considered free under federal law, and proposed Medicare Advantage Star Ratings target top performers.

A new prevalence study shows more people are living beyond age 65 with type 1 diabetes (T1D).

Determining the roles that various inflammatory markers and pathways play in lower-risk myelodysplastic syndromes (MDS) could lead to therapies that keep disease progression at bay.

A panel of ophthalmologists defined points of consensus for suprachoroidal space injections based on current published evidence.

In a European expert consensus statement, researchers discover the exciting breakthroughs for patients with alopecia areata (AA). This article explores the unlocked potential of combination therapies and targeted biologics to regrow hair and transform lives.

This study provides a comprehensive review of both established and emerging prognostic markers in chronic lymphocytic leukemia (CLL), and their role in predicting disease, treatment response, and overall survival.

June 19 is marked as World Sickle Cell Awareness Day, granting the opportunity to reflect on the current state of treatment, access, equity, and more that impacts patients living with sickle cell disease.

Study findings show eculizumab is effective and well tolerated in reducing disease burden in adolescents with refractory anti-acetylcholine receptor antibody–positive generalized myasthenia gravis.

The home-based care model offers a promising strategy for improving quality of care, while also reducing health care spending.

Encouraging trends were seen with osimertinib and platinum-pemetrexed chemotherapy in patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC) in the phase 3 FLAURA2 study.

The albumin-bilirubin score is a reliable predictor of treatment response for hepatocellular carcinoma (HCC) after yttrium 90 transarterial radioembolization (TARE).

A poster from the 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema (RAVE) conference held in Chicago, Illinois presented results of a clinical trial for patients with alopecia areata (AA). The trial used rilecitinib and showed promising results in patients with AA after most patients achieved significant hair regrowth following 15 months of treatment.

The treatment regimen not only significantly improved progression-free survival (PFS) for patients with advanced stage classic Hodgkin lymphoma but was also better tolerated compared with a 20-year-old regimen being used.

Vaccination against seasonal influenza and respiratory syncytial virus (RSV) in patients with high-risk heart failure was found safe with low incidence of mild adverse events (AEs).

A Chinese study shows hypertension management led by nonphysicians can be safe and effective.

Over $3 billion in payments were issued to health care providers and suppliers; a recent poll highlights growing demand to alleviate medical debt; preliminary data show a decrease in uninsured individuals since 2019.

For the third episode in our special Pride Month series, we speak with Patrick McGovern, CEO of Callen-Lorde since August of 2023 and an outspoken advocate for HIV; lesbian, gay, bisexual, transgender, queer, plus (LGBTQ+); and community health.

Patients with the highest biologically active adrenomedullin (bio-ADM) levels at baseline were 114% more likely to die from any cause or be readmitted to the hospital for heart failure within 6 months compared with patients with the lowest levels.

The FDA approved pembrolizumab (Keytruda) plus carboplatin and paclitaxel, followed by single-agent pembrolizumab, in adult patients with primary advanced or recurrent endometrial carcinoma.

Ageing with HIV comes with greater risks of other health complications; behavioral counseling programs for obesity are scare and often not covered by insurance; the surgeon general is calling for legislative action to protect youth when they interact with social media.

With its recent approvals around the world to treat newly diagnosed and relapsed/refractory diffuse large B-cell lymphoma (DLBCL), the antibody-drug conjugate polatuzumab vedotin is changing regimens for current and future patients, with manageable adverse effects.

A recent review found that benzene exposure due to work may be linked to the development of colorectal cancer.

Notably, adolescents and young adults (AYA) living with type 1 diabetes (T1D) who reported more comfort with self-management tended to have worse glycemic control.

The late-breaking oral session at the European Hematology Association (EHA) 2024 Congress featured new data from abstracts submitted after the deadline, including both interventional and foundational science.

The FDA has approved durvalumab combined with carboplatin and paclitaxel, followed by single-agent durvalumab.

At a session of the European Hematology Association 2024 Congress, presenters shared updates from trials of treatment strategies for newly diagnosed multiple myeloma (MM).

Two posters presented at the 2024 American Society of Clinical Oncology annual meeting revealed real-world data on the outcomes and management strategies associated with melanoma during pregnancy.

Researchers have found that specific genetic markers may increase the risk of cardiovascular adverse effects in patients using Bruton’s tyrosine kinase (BTK) inhibitors.

Investigators from Germany conducted a systematic review of different MRI features in soft tissue sarcoma (STS) that are used to infer tumor histological grade.

The Center on Health Equity & Access shares the latest news, research, and expert insights on developments related to health disparities, gaps in care, and initiatives to address them.